Recurrent Diffuse Large B-Cell Lymphoma Clinical Trials in Sacramento, California

4 studies are recruiting for recurrent diffuse large b-cell lymphoma in Sacramento, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

   This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Locations

   9 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05272384 on ClinicalTrials.gov

2. Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

   This phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or has not responded to…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT05052528 on ClinicalTrials.gov

3. Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

   This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapy in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previ…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT06854159 on ClinicalTrials.gov

4. Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

   This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X] or gemcitabine and oxaliplatin [Gem/Ox]) and autolog…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT06905509 on ClinicalTrials.gov